MNTA Share Price

Open 19.00 Change Price %
High 19.25 1 Day 0.00 0.00
Low 18.60 1 Week 0.10 0.53
Close 19.00 1 Month 3.90 25.83
Volume 414508 1 Year 9.08 91.53
52 Week High 19.90
52 Week Low 7.86
MNTA Important Levels
Resistance 2 19.60
Resistance 1 19.35
Pivot 18.95
Support 1 18.65
Support 2 18.40
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
ASTI 0.00 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
CSCO 33.72 0.36%
More..
NASDAQ USA Top Gainers Stocks
EDMC 0.02 100.00%
LIWA 0.02 100.00%
QKLS 0.20 100.00%
MOSY 3.50 54.19%
LOCM 0.09 50.00%
MYRX 0.06 50.00%
LMIA 13.66 48.64%
CPSL 0.10 42.86%
WRES 0.09 28.57%
BSDM 0.62 26.53%
More..
NASDAQ USA Top Losers Stocks
GPRC 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
QTWW 0.08 -50.00%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)

MNTA Technical Analysis 5
As on 17th Feb 2017 MNTA Share Price closed @ 19.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 12.35 & Strong Buy for SHORT-TERM with Stoploss of 16.03 we also expect STOCK to react on Following IMPORTANT LEVELS.
MNTA Target for February
1st Target up-side 21.69
2nd Target up-side 23.65
3rd Target up-side 25.6
1st Target down-side 16.11
2nd Target down-side 14.15
3rd Target down-side 12.2
MNTA Other Details
Segment EQ
Market Capital 681705792.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.momentapharma.com
MNTA Address
MNTA
675 West Kendall Street
Cambridge, MA 02142
United States
Phone: 617-491-9700
Fax: 617-621-0431
MNTA Latest News
Interactive Technical Analysis Chart Momenta Pharmaceuticals, Inc. ( MNTA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Momenta Pharmaceuticals, Inc.
MNTA Business Profile
Momenta Pharmaceuticals, Inc. (Momenta) is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). This results in a diversified product pipeline of complex generic, follow-on biologic (FOB) and novel drugs. The Company�s complex generic programs target marketed products, which were originally approved by the United States Food and Drug Administration (FDA) as New Drug Applications (NDAs). Its M356, is designed to be a generic version of Copaxone (glatiramer acetate injection), a drug that is indicated for the reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis (RRMS). During the year ended December 31, 2011, it acquired the assets of Virdante. On February 13, 2012 it entered into a global collaboration (Baxter Agreement) with Baxter International Inc.